An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)
Phase of Trial: Phase 0
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 Planned number of patients changed from 16 to 24.
- 10 Jul 2017 Planned End Date changed from 31 Mar 2018 to 31 Oct 2018.